
Researcher
Hupperts, R.M.M.
Endowed chair - Affiliated chair, H/MS
View graph of relations
- 2019
- PublishedTiane, A., Schepers, M., Rombaut, B., Hupperts, R., Prickaerts, J., Hellings, N., ... Vanmierlo, T. (2019). From OPC to Oligodendrocyte: An Epigenetic Journey. Cells, 8(10), [1236]. https://doi.org/10.3390/cells8101236
- PublishedRolf, L., Smolders, J., van den Ouweland, J., Hupperts, R., & Damoiseaux, J. (2019). Correlation of different cellular assays to analyze T cell-related cytokine profiles in vitamin D-3-supplemented patients with multiple sclerosis. Molecular Immunology, 105, 198-204. https://doi.org/10.1016/j.molimm.2018.12.001
- 2018
- PublishedDiaz, G. M., Hupperts, R., Fraussen, J., & Somers, V. (2018). Dimethyl fumarate treatment in multiple sclerosis: Recent advances in clinical and immunological studies. Autoimmunity Reviews, 17(12), 1240-1250. https://doi.org/10.1016/j.autrev.2018.07.001
- PublishedRolf, L., Muris, A-H., Mathias, A., Du Pasquier, R., Koneczny, I., Disanto, G., ... Hupperts, R. (2018). Exploring the effect of vitamin D-3 supplementation on the anti-EBV antibody response in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 24(10), 1280-1287. https://doi.org/10.1177/1352458517722646
- PublishedDiaz, G. M., Fraussen, J., Van Wijmeersch, B., Hupperts, R., & Somers, V. (2018). Dimethyl fumarate induces a persistent change in the composition of the innate and adaptive immune system in multiple sclerosis patients. Scientific Reports, 8, [8194]. https://doi.org/10.1038/s41598-018-26519-w
- PublishedRolf, L., Damoiseaux, J., Huitinga, I., Kimenai, D., van den Ouweland, J., Hupperts, R., & Smolders, J. (2018). Stress-Axis Regulation by Vitamin D-3 in Multiple Sclerosis. Frontiers in Neurology, 9, [263]. https://doi.org/10.3389/fneur.2018.00263
- PublishedLieben, C. K., Blokland, A., Deutz, N. E., Jansen, W., Han, G., & Hupperts, R. M. (2018). Intake of tryptophan-enriched whey protein acutely enhances recall of positive loaded words in patients with multiple sclerosis. Clinical Nutrition, 37(1), 321-328. https://doi.org/10.1016/j.clnu.2016.12.029
- PublishedRolf, L., Muris, A-H., Theunissen, R., Hupperts, R., Damoiseaux, J., & Smolders, J. (2018). Vitamin D-3 supplementation and the IL-2/IL-2R pathway in multiple sclerosis: Attenuation of progressive disturbances? Journal of Neuroimmunology, 314, 50-57. https://doi.org/10.1016/j.jneuroim.2017.11.007
- PublishedSmolders, J., Hupperts, R., & Damoiseaux, J. (2018). Chapter 8 - The Way Forward With Vitamin D in Multiple Sclerosis. In A. Minagar (Ed.), Neuroinflammation (Second Edition) (pp. 175-191). Academic Press. https://doi.org/10.1016/B978-0-12-811709-5.00009-0
- 2017
- PublishedHavrdova, E., Arnold, D. L., Cohen, J. A., Hartung, H-P., Fox, E. J., Giovannoni, G., ... Coles, A. J. (2017). Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy. Neurology, 89(11), 1107-1116. https://doi.org/10.1212/WNL.0000000000004313
- PublishedColes, A. J., Cohen, J. A., Fox, E. J., Giovannoni, G., Hartung, H-P., Havrdova, E., ... Arnold, D. L. (2017). Alemtuzumab CARE-MS II 5-year follow-up Efficacy and safety findings. Neurology, 89(11), 1117-1126. https://doi.org/10.1212/wnl.0000000000004354
- PublishedLorscheider, J., Jokubaitis, V. G., Spelman, T., Izquierdo, G., Lugaresi, A., Havrdova, E., ... Kalincik, T. (2017). Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS. Neurology, 89(10), 1050-1059. https://doi.org/10.1212/WNL.0000000000004330
- PublishedKalincik, T., Manouchehrinia, A., Sobisek, L., Jokubaitis, V., Spelman, T., Horakova, D., ... MSBase Study Group (2017). Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. Brain, 140(9), 2426-2443. https://doi.org/10.1093/brain/awx185
- Published
- PublishedRolf, L., Muris, A-H., Bol, Y., Damoiseaux, J., Smolders, J., & Hupperts, R. (2017). Vitamin D3 supplementation in multiple sclerosis: Symptoms and biomarkers of depression. Journal of the Neurological Sciences, 378, 30-35. https://doi.org/10.1016/j.jns.2017.04.017
- Publishedde Jong, H. J. I., Kingwell, E., Shirani, A., Tervaert, J. W. C., Hupperts, R., Zhao, Y., ... British Columbia Multiple Sclerosi (2017). Evaluating the safety of beta-interferons in MS A series of nested case-control studies. Neurology, 88(24), 2310-2320. https://doi.org/10.1212/WNL.0000000000004037
- Published
- PublishedIaffaldano, P., Simone, M., Lucisano, G., Ghezzi, A., Coniglio, G., Morra, V. B., ... Trojano, M. (2017). Prognostic Indicators in Pediatric Clinically Isolated Syndrome. Annals of Neurology, 81(5), 729-739. https://doi.org/10.1002/ana.24938
- PublishedKalincik, T., Brown, J. W. L., Robertson, N., Willis, M., Scolding, N., Rice, C. M., ... Grp, MSB. S. (2017). Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. Lancet Neurology, 16(4), 271-281. https://doi.org/10.1016/S1474-4422(17)30007-8
- PublishedMontalban, X., Hauser, S. L., Kappos, L., Arnold, D. L., Bar-Or, A., Comi, G., ... Wolinsky, J. S. (2017). Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. New England Journal of Medicine, 376(3), 209-220. https://doi.org/10.1056/NEJMoa1606468
- PublishedKnippenberg, S., Smolders, J., van den Maegdenbergh, M., Porro, G., Damoiseaux, J., & Hupperts, R. (2017). Response to "Vitamin D status is negatively correlated with retinal nerve fiber layer thickness in relapsing-remitting MS patients without acute optic neuritis" by Knippenberg et al. Multiple Sclerosis Journal, 23(1), 129-129. https://doi.org/10.1177/1352458516652951
- PublishedKnippenberg, S., Smolders, J., van den Maegdenbergh, M., Porro, G., Damoiseaux, J., & Hupperts, R. (2017). Vitamin D status is negatively correlated with retinal nerve fiber layer thickness in relapsing-remitting MS patients without acute optic neuritis. Multiple Sclerosis Journal, 23(1), 128-129. https://doi.org/10.1177/1352458516652950
- 2016
- PublishedClaes, N., Fraussen, J., Vanheusden, M., Hellings, N., Stinissen, P., Van Wijmeersch, B., ... Somers, V. (2016). Age-Associated B Cells with Proinflammatory Characteristics Are Expanded in a Proportion of Multiple Sclerosis Patients. Journal of Immunology, 197(12), 4576-4583. https://doi.org/10.4049/jimmunol.1502448
- PublishedFraussen, J., Claes, N., Van Wijmeersch, B., van Horssen, J., Stinissen, P., Hupperts, R., & Somers, V. (2016). B cells of multiple sclerosis patients induce autoreactive proinflammatory T cell responses. Clinical Immunology, 173, 124-132. https://doi.org/10.1016/j.clim.2016.10.001
- PublishedMuris, A-H., Smolders, J., Rolf, L., Thewissen, M., Hupperts, R., & Damoiseaux, J. (2016). Immune regulatory effects of high dose vitamin D-3 supplementation in a randomized controlled trial in relapsing remitting multiple sclerosis patients receiving IFN beta; the SOLARIUM study. Journal of Neuroimmunology, 300, 47-56. https://doi.org/10.1016/j.jneuroim.2016.09.018
- PublishedGasperini, C., Hupperts, R., Lycke, J., Short, C., McNeill, M., Zhong, J., & Mehta, L. R. (2016). Prolonged-release fampridine treatment improved subject-reported impact of multiple sclerosis: Item-level analysis of the MSIS-29. Journal of the Neurological Sciences, 370, 123-131. https://doi.org/10.1016/j.jns.2016.08.052
- PublishedMuris, A-H., Rolf, L., Broen, K., Hupperts, R., Damoiseaux, J., & Smolders, J. (2016). A low vitamin D status at diagnosis is associated with an early conversion to secondary progressive multiple sclerosis. Journal of Steroid Biochemistry and Molecular Biology, 164, 254-257. https://doi.org/10.1016/j.jsbmb.2015.11.009
- PublishedCARE-MS I and CARE-MS II Coinvestigators (2016). Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS. Neurology, 87(14), 1464-1472. https://doi.org/10.1212/WNL.0000000000003169
- PublishedKister, I., Spelman, T., Alroughani, R., Lechner-Scott, J., Duquette, P., Grand'Maison, F., ... Butzkueven, H. (2016). Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study. Journal of Neurology Neurosurgery and Psychiatry, 87(10), 1133-1137. https://doi.org/10.1136/jnnp-2016-313760
- PublishedBenefit study group (2016). The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. Neurology, 87(10), 978-987. https://doi.org/10.1212/WNL.0000000000003078
- PublishedLorscheider, J., Buzzard, K., Jokubaitis, V., Spelman, T., Havrdova, E., Horakova, D., ... Kalincik, T. (2016). Defining secondary progressive multiple sclerosis. Brain, 139, 2395-2405. https://doi.org/10.1093/brain/aww173
- PublishedLaGanke, C., De Seze, J., Freedman, M. S., Habek, M., Hupperts, R. M. M., Limmroth, V., ... Havrdova, E. (2016). Durable suppression of disease activity by alemtuzumab in the absence of continuous treatment over 6 years in patients with active relapsing-remitting multiple sclerosis and an inadequate response to prior therapy (CARE-MS II). Multiple Sclerosis Journal, 22, 327-328.
- PublishedRolf, L., Damoiseaux, J., Hupperts, R., Huitinga, I., & Smolders, J. (2016). Network of nuclear receptor ligands in multiple sclerosis: Common pathways and interactions of sex-steroids, corticosteroids and vitamin D-3-derived molecules. Autoimmunity Reviews, 15(9), 900-910. https://doi.org/10.1016/j.autrev.2016.07.002
- PublishedBrandt-Wouters, E., Gerlach, O. H. H., & Hupperts, R. M. M. (2016). The effect of postpartum intravenous immunoglobulins on the relapse rate among patients with multiple sclerosis. International Journal of Gynecology & Obstetrics, 134(2), 194-196. https://doi.org/10.1016/j.ijgo.2016.01.008
- PublishedJokubaitis, V. G., Spelman, T., Kalincik, T., Lorscheider, J., Havrdova, E., Horakova, D., ... Trojano, M. (2016). Predictors of Long-Term Disability Accrual in Relapse-Onset Multiple Sclerosis. Annals of Neurology, 80(1), 89-100. https://doi.org/10.1002/ana.24682
- PublishedMuris, A-H., Smolders, J., Rolf, L., Klinkenberg, L. J. J., van der Linden, N., Meex, S., ... Hupperts, R. (2016). Vitamin D Status Does Not Affect Disability Progression of Patients with Multiple Sclerosis over Three Year Follow-Up. PLOS ONE, 11(6), [e0156122]. https://doi.org/10.1371/journal.pone.0156122
- PublishedSpelman, T., Kalincik, T., Jokubaitis, V., Zhang, A., Pellegrini, F., Wiendl, H., ... Butzkueven, H. (2016). Comparative efficacy of first-line natalizumab vs IFN-beta or glatiramer acetate in relapsing MS. Neurology: Clinical Practice, 6(2), 102-115. https://doi.org/10.1212/CPJ.0000000000000227
- PublishedINFORMS study investigators (2016). Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet, 387(10023), 1075-1084. https://doi.org/10.1016/S0140-6736(15)01314-8
- PublishedTeriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group, & Hupperts, R. (2016). Long-term safety and efficacy of teriflunomide Nine-year follow-up of the randomized TEMSO study. Neurology, 86(10), 920-930. https://doi.org/10.1212/WNL.0000000000002441
- PublishedRolf, L., Muris, A-H., Hupperts, R., & Damoiseaux, J. (2016). Illuminating vitamin D effects on B cells - the multiple sclerosis perspective. Immunology, 147(3), 275-284. https://doi.org/10.1111/imm.12572
- PublishedJongen, P. J., Lemmens, W. A., Hupperts, R., Hoogervorst, E. L. J., Schrijver, H. M., Slettenaar, A., ... Donders, R. (2016). Persistence and adherence in multiple sclerosis patients starting glatiramer acetate treatment: assessment of relationship with care received from multiple disciplines. Patient Preference and Adherence, 10, 909-917. https://doi.org/10.2147/PPA.S108121
- 2015
- PublishedKalincik, T., Cutter, G., Spelman, T., Jokubaitis, V., Havrdova, E., Horakova, D., ... Butzkueven, H. (2015). Defining reliable disability outcomes in multiple sclerosis. Brain, 138. https://doi.org/10.1093/brain/awv258
- PublishedBayas, A., Ouallet, J. C., Kallmann, B., Hupperts, R., Fulda, U., & Marhardt, K. (2015). Adherence to, and effectiveness of, subcutaneous interferon beta-1a administered by RebiSmart (R) in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study. Expert Opinion on Drug Delivery, 12(8), 1239-1250. https://doi.org/10.1517/17425247.2015.1057567
- PublishedKalincik, T., Jokubaitis, V., Izquierdo, G., Duquette, P., Girard, M., Grammond, P., ... Butzkueven, H. (2015). Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 21(9), 1159-1171. https://doi.org/10.1177/1352458514559865
- PublishedRibbons, K. A., McElduff, P., Boz, C., Trojano, M., Izquierdo, G., Duquette, P., ... Lechner-Scott, J. (2015). Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS. PLOS ONE, 10(6), [e0122686]. https://doi.org/10.1371/journal.pone.0122686
- PublishedBergamaschi, R., Montomoli, C., Mallucci, G., Lugaresi, A., Izquierdo, G., Grand'Maison, F., ... Trojano, M. (2015). BREMSO: a simple score to predict early the natural course of multiple sclerosis. European Journal of Neurology, 22(6), 981-989. https://doi.org/10.1111/ene.12696
- PublishedJokubaitis, V. G., Spelman, T., Kalincik, T., Izquierdo, G., Grand'Maison, F., Duquette, P., ... Trojano, M. (2015). Predictors of disability worsening in clinically isolated syndrome. Annals of Clinical and Translational Neurology, 2(5), 479-491. https://doi.org/10.1002/acn3.187
- PublishedSpelman, T., Kalincik, T., Zhang, A., Pellegrini, F., Wiendl, H., Kappos, L., ... Butzkueven, H. (2015). Comparative efficacy of switching to natalizumab in active multiple sclerosis. Annals of Clinical and Translational Neurology, 2(4), 373-387. https://doi.org/10.1002/acn3.180
- PublishedHe, A., Spelman, T., Jokubaitis, V., Havrdova, E., Horakova, D., Trojano, M., ... Kalincik, T. (2015). Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis. JAMA Neurology, 72(4), 405-413. https://doi.org/10.1001/jamaneurol.2014.4147
- PublishedPeelen, E., Muris, A. H., Damoiseaux, J., Knippenberg, S., Broens, K., Smolders, J., ... Thewissen, M. (2015). GM-CSF production by CD4+ T cells in MS patients: Regulation by regulatory T cells and vitamin D. Journal of Neuroimmunology, 280, 36-42. https://doi.org/10.1016/j.jneuroim.2015.02.007